FUNDAMENTALS · Fundamentals · US Healthcare

Capricor Therapeutics (CAPR) Fundamentals 2026 — Revenue Analysis | SniperIQ

Capricor Therapeutics (CAPR) is a US-listed Healthcare company in Biotechnology with a market capitalization of $881M, trading at

9.27 on the NASDAQ. This SniperIQ fundamentals page covers Capricor Therapeutics's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$881M
Net Margin0.0%

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Capricor Therapeutics's market cap?

Capricor Therapeutics (CAPR) has a market capitalization of approximately $881M, trading at

9.27 on the NASDAQ. Market cap moves with the live share price.

What is Capricor Therapeutics's P/E ratio?

Capricor Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Capricor Therapeutics?

Capricor Therapeutics runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does Capricor Therapeutics pay a dividend?

Capricor Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Capricor Therapeutics financially healthy?

Capricor Therapeutics carries a debt-to-equity ratio of 0.08x and a current ratio of 8.42x, with a market beta of 0.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Capricor Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Capricor Therapeutics (CAPR) the key facts are: market cap $881M, 52-week range 4.3-40.37. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Capricor Therapeutics's full fundamentals live

Get Capricor Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: OPKO Health (OPK) fundamentals · InMode (INMD) fundamentals · Geron (GERN) fundamentals · Theravance Biopharma (TBPH) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons